[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527045":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":33,"locations":41,"responsibleParty":61,"collaborators":11,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":11,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":11,"studyType":77,"phases":78,"briefSummary":81,"conditions":82,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"October 6 University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Metformin","ACTIVE_COMPARATOR",null,[13],"Drug: Metformin Hydrochloride tablet",{"label":15,"type":10,"description":11,"interventionNames":16},"Vildagliptin",[17],"Drug: Vildagliptin 50 MG",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Metformin Hydrochloride tablet","Metformin Hydrochloride 850 mg oral tablet",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Vildagliptin 50 MG","Vildagliptin 50 MG oral tablets",[15],[29],{"name":30,"affiliation":31,"role":32},"ahmed hussein, PhD","october 6 university hospital","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"ahmed hussein, phD","CONTACT","01001749605","ahmedhussein.med@o6u.edu.eg",{"name":40,"role":36,"phone":11,"phoneExt":11,"email":38},"ahmed hussein",[42],{"facility":43,"status":44,"city":45,"state":11,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"October 6 university hospital","RECRUITING","Giza","12585","Egypt","EG",{"type":50,"coordinates":51},"Point",[52,53],31.20861,30.00944,{"lat":53,"lon":52},[56,58],{"name":57,"role":36,"phone":37,"phoneExt":11,"email":11},"ahmed M. A, phD",{"name":59,"role":36,"phone":60,"phoneExt":11,"email":11},"Hanan elhanafy","01281084864",{"type":32,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"engy wahsh","LECTURER OF CLINICAL PHARMACY","100527045","phase-2-efficacy-of-vildagliptin-versus-metformin-in-poly-cystic-ovary-syndrome-100527045",false,"NCT06142656","Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome","Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome: A Randomized Clinical Trial","Inclusion Criteria:\n\n-Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.\n\nExclusion Criteria:\n\n* Patients with history of diabetes mellitus (Type 1 or 2).\n* Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months\n* Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors\n* Eating disorders (anorexia, bulimia) or gastrointestinal disorders","FEMALE","18 Years","50 Years",{"count":75,"type":76},60,"ESTIMATED","INTERVENTIONAL",[79,80],"PHASE2","PHASE3","Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM",[83],"Poly Cystic Ovary Syndrome","2025-07-28",{"date":86,"type":87},"2025-07-30","ACTUAL",{"date":89,"type":87},"2023-11-25",{"date":91,"type":76},"2026-02-01",{"name":5,"class":6},1]